Cargando…
Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis - a double-blind, placebo-controlled study
BACKGROUND: Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. AIM: To assess the efficacy and safety of pancreatin (Creon 40000 MMS) in treating PEI due to chronic pancreatitis (CP). METHODS: This was a 1-week, dou...
Autores principales: | Thorat, V, Reddy, N, Bhatia, S, Bapaye, A, Rajkumar, J S, Kini, D D, Kalla, M M, Ramesh, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528066/ https://www.ncbi.nlm.nih.gov/pubmed/22762290 http://dx.doi.org/10.1111/j.1365-2036.2012.05202.x |
Ejemplares similares
-
Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension
por: Seiler, C M, et al.
Publicado: (2013) -
Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS
por: Maev, Igor V., et al.
Publicado: (2020) -
Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Petersen, Karl-Uwe
Publicado: (2021) -
Kreon(®) (Creon(®)) vs. Lipancrea(®): In Vitro Comparison of Two Encapsulated Pancreatin Preparations
por: Hartmann, Sven, et al.
Publicado: (2022) -
Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Maev, Igor V., et al.
Publicado: (2021)